Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
Rhea-AI Summary
Cardiff Oncology (Nasdaq: CRDF) will present updated Phase 2 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) at ASCO 2026. The rapid oral presentation (Abstract #3510) is scheduled for June 2, 2026, 8:00-9:30 AM CDT.
The abstract will be publicly available May 21, 2026, and the presentation will be posted on the company’s Scientific Publications page after ASCO.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CRDF
On the day this news was published, CRDF declined 7.30%, reflecting a notable negative market reaction. Argus tracked a peak move of +3.2% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $9M from the company's valuation, bringing the market cap to $120.32M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CRDF is down 1.11% with 2 tracked biotech peers (ACTU, GNLX) also moving down (median move about -6.3%), indicating a broader sector-driven downswing rather than a company‑specific reaction.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Phase 2 mCRC update | Positive | -32.0% | Reported strong Phase 2 CRDF‑004 efficacy and PFS data in first-line mCRC. |
| Dec 08 | CMML trial data | Positive | +3.0% | Disclosed Phase 1 CMML data with preliminary efficacy in about 40% of patients. |
| Jul 29 | mCRC efficacy data | Positive | -24.8% | Announced positive randomized Phase 2 CRDF‑004 data with higher ORR vs control. |
| Apr 15 | Trial enrollment complete | Neutral | -4.4% | Completed enrollment in Phase 2 CRDF‑004 trial across 41 U.S. clinical sites. |
| Dec 10 | Initial mCRC data | Positive | +54.9% | Reported positive initial CRDF‑004 results with higher ORR at 30 mg dose. |
Clinical trial announcements for onvansertib have often been positive scientifically but produced mixed price reactions, including notable selloffs on upbeat mCRC data and an average same-tag move of -0.65%.
Over the last 18 months, Cardiff Oncology has repeatedly highlighted Phase 2 CRDF‑004 progress in first-line RAS‑mutated mCRC, including positive initial data in Dec 2024, enrollment completion in Apr 2025, and multiple efficacy updates showing superior ORR and PFS versus standard of care. An additional investigator‑sponsored CMML study showed preliminary activity but is not a current focus. Today’s ASCO 2026 rapid oral presentation notice fits this pattern of incremental clinical disclosure around onvansertib’s mCRC program.
Historical Comparison
Over five prior clinical‑trial updates, CRDF’s average 1‑day move was -0.65%, with both sharp rallies and steep selloffs on onvansertib data.
Clinical disclosures show a progression from initial CRDF‑004 mCRC data to dose optimization, enrollment completion, and repeated efficacy/PFS updates supporting a planned registrational program.
Market Pulse Summary
The stock moved -7.3% in the session following this news. A negative reaction despite a data-focused announcement fits prior patterns where strong clinical updates sometimes coincided with selling pressure. Past CRDF‑004 disclosures included sizeable moves both up and down around high ORR and PFS metrics. Such volatility has often reflected market skepticism about durability, trial design, or eventual registrational prospects rather than the absence of encouraging efficacy signals in the underlying data.
Key Terms
plk1 inhibition medical
phase 2 medical
randomized medical
folfiri medical
folfox medical
bevacizumab medical
metastatic colorectal cancer medical
rapid oral presentation technical
AI-generated analysis. Not financial advice.
SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present updated data from CRDF-004, a randomized dose-finding Phase 2 clinical trial evaluating onvansertib in combination with standard of care (SoC) regimens (FOLFIRI/bevacizumab (bev) or FOLFOX/bev) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). The data will be reviewed in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2 in Chicago.
Rapid Oral Presentation Details:
Abstract Title: Onvansertib plus standard-of-care chemotherapy plus bevacizumab in first-line RAS-mutated metastatic colorectal cancer (mCRC): Interim results from the phase 2 randomized CRDF-004 trial
Abstract Number: 3510
Session Title: Gastrointestinal Cancer—Colorectal and Anal
Session Date and Time: June 2, 2026, 8:00-9:30 AM CDT
The abstract will be publicly available on Thursday, May 21, 2026 on ASCO’s website, and the presentation will be made available on the Scientific Publications page of the Company’s website following its presentation.
About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer. It is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML).
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.
For more information, please visit https://www.cardiffoncology.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed; our need for additional financing; risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.
Investor Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
